A study found that a blood test detecting ctDNA after surgery more accurately predicts recurrence and survival in patients with stage 3 colon cancer.

The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer, NBC News reported. The test isn't meant to replace colonoscopies, but is ...

Liquid biopsies have transformed cancer testing. These tests detect signs of cancer using a simple blood draw instead of removing tissue from the body. Traditional biopsies involve surgery, needles, ...

A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that while blood-based tests offer a more convenient option for colorectal cancer screening, only 49% of ...

The ctDNA test showed 79.2% sensitivity and 91.5% specificity for CRC detection in a diverse cohort. The study met primary end points but had limited sensitivity for advanced precancerous lesions.

Active-duty service members and eligible family members now have access to blood test for colorectal cancer screening with no copay Shield is the first and only blood test approved by the FDA as a ...

A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery, according to new study in JAMA Oncology.

Around four years ago, now 77-year-old John Gormly went for what was supposed to be a routine blood test. But the results were life-changing. The test suggested Gormly had colon cancer, which a ...

If you're in your 40s, you might think colon cancer is something to worry about decades from now. But alarming new research ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and ...